Years after Keytruda, Roche's Tecentriq monotherapy wins first-line NSCLC approval. So does it matter?
Years after Keytruda, patients with previously untreated non-small cell lung cancer (NSCLC) finally have a new checkpoint inhibitor monotherapy option: Roche’s Tecentriq.
Merck’s star drug captured this ripe indication in 2016, winning the battle for checkpoint inhibitor supremacy years ago. On Monday, the FDA approved Roche’s Tecentriq on its own for newly diagnosed, metastatic patients without EGFR or ALK mutations whose tumors carry levels of the biomarker PD-L1 registering at 50% or greater.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.